For a phase I clinical trial, the results are the Holy Grail. Yet researchers from the University of Louisville and Brigham and Women's Hospital today reported just such almost-never-attained data.
It marked sustained improvement in all patients with zero adverse effects.
Advertisement
In a Late-Breaking Clinical Trial session at the American Heart Association Scientific Sessions 2012 meeting, Roberto Bolli, M.D., of the University of Louisville and Piero Anversa, M.D., of Brigham and Women's Hospital, Boston, presented data from their groundbreaking research in the use of autologous adult stem cells with patients who had previous heart attacks.
They report that after two years, all patients receiving the stem cell therapy show improvement in heart function, with an overall 12.9 absolute unit increase in left ventricular ejection fraction (LVEF), a standard measure of heart function that shows the amount of blood ejected from the left ventricle during a heartbeat. No adverse effects resulting from the therapy were seen. Moreover, MRIs performed on nine patients in the trial showed evidence of myocardial regeneration - new heart tissue replacing former dead tissue killed by heart attack.
Source: Eurekalert
Source: Eurekalert
Advertisement
Advertisement
This site complies with the HONcode standard for trustworthy health information: 
